PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
36.85
+0.17 (+0.46%)
At close: 4:01PM EDT

36.95 +0.10 (0.27%)
After hours: 6:48PM EDT

Stock chart is not supported by your current browser
Previous Close36.68
Open36.80
Bid36.77 x 12000
Ask36.95 x 100
Day's Range36.75 - 37.10
52 Week Range31.67 - 39.43
Volume19,360,179
Avg. Volume25,241,191
Market Cap219.206B
Beta0.95
PE Ratio (TTM)10.48
EPS (TTM)3.52
Earnings DateMay 1, 2018
Forward Dividend & Yield1.36 (3.70%)
Ex-Dividend Date2018-02-01
1y Target Est40.11
Trade prices are not sourced from all markets
  • Business Wire6 hours ago

    Pfizer Hosts Annual Meeting of Shareholders

    The board of directors of Pfizer Inc. today declared a 34-cent second-quarter 2018 dividend on the company’s common stock, payable June 1, 2018, to shareholders of record at the close of business on May 11, 2018. The second-quarter 2018 cash dividend will be the 318th consecutive quarterly dividend paid by Pfizer. “In 2017, we returned nearly $12.7 billion to shareholders through dividends and share repurchases,” said Ian Read, chairman and chief executive officer.

  • Reuters8 hours ago

    Bristol-Myers raises 2018 forecast, some sales disappoint

    Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down ...

  • Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
    Zacks10 hours ago

    Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?

    With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.

  • Analyst Recommendations for Biogen in April
    Market Realist11 hours ago

    Analyst Recommendations for Biogen in April

    In March, Biogen (BIIB) entered into an agreement with Pfizer (PFE) to acquire Pfizer’s investigational drug PF-04958242, a Phase 2b–ready AMPA (α-amino-3-hydroxy-5 methyl-4-isoxazolepropionic acid) receptor potentiator for cognitive impairment related to schizophrenia. Biogen will make an upfront payment of $75 million to Pfizer and up to $515 million as additional development and commercialization milestone payments. Pfizer is also subject to receive tiered royalty payments from Biogen.

  • Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth
    Market Realist11 hours ago

    Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth

    In 4Q17, Novo Nordisk’s (NVO) hemophilia drugs NovoSeven and NovoEight generated revenues of 2.4 billion Danish kroner and 274 billion Danish kroner, respectively. That’s a ~3% and 1% YoY (year-over-year) growth in local currency.

  • 3 Top Dividend Stocks With Yields Over 3%
    Motley Fool13 hours ago

    3 Top Dividend Stocks With Yields Over 3%

    A 10-year U.S. Treasury note may yield 3% right now, but these Fools think these stocks are a better investment.

  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realistyesterday

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
    Market Realistyesterday

    GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings

    GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.

  • Analysts’ Estimates for Sanofi’s 1Q18 Earnings
    Market Realistyesterday

    Analysts’ Estimates for Sanofi’s 1Q18 Earnings

    Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.

  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realistyesterday

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realistyesterday

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
    Market Realistyesterday

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.

  • Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?
    Zacksyesterday

    Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?

    While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

  • Why Incyte Stock Fell ~9% on April 24
    Market Realistyesterday

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress
    Market Realistyesterday

    Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress

    Gilead Sciences (GILD) is currently studying an investigational therapy, filgotinib, in five Phase 3 trials as a treatment option for RA (rheumatoid arthritis), ulcerative colitis, and Crohn’s disease. The company is studying this therapy for RA in its FINCH 1, 2, and 3 trials. While the FINCH 2 study has completed enrolment, FINCH 1 and FINCH 3 are expected to complete enrolment in 2Q18 and 3Q18, respectively.

  • Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
    Market Realist2 days ago

    Biktarvy Could Be a Major Driver for Gilead Sciences in 2018

    Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen

  • MarketWatch2 days ago

    Wegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA says

    In spite of reports that Wegmans pharmacies are out of stock of the EpiPen allergic reaction treatment, the Food and Drug Administration is not currently aware of any U.S. shortage, though the regulator continues to monitor the supply, spokesperson Lauren Smith Dyer. Pfizer , which manufactures the Mylan product through one of its business units, said that it is currently shipping products but supplies may vary from pharmacy to pharmacy.

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist2 days ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer

    The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer

  • Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
    Market Realist2 days ago

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

  • Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance
    Market Realist2 days ago

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. (LLY) reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17. The company beat Wall Street analysts’ estimates for earnings-per-share (or EPS) and revenues in 1Q18 and reported EPS of $1.34 on revenues of ~$5.7 billion, compared to an estimated EPS of $1.14 on revenues of ~$5.5 billion.

  • Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
    Motley Fool2 days ago

    Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma

    It's a lot easier to be patient once those quarterly payments start adding up.

  • Don't Get Greedy With Novavax, Inc. Stock
    Motley Fool3 days ago

    Don't Get Greedy With Novavax, Inc. Stock

    Novavax's abysmal track record should be a huge red flag for potential shareholders.

  • Here’s why Amazon won’t go into pharma: hedge fund billionaire
    Yahoo Finance Video2 days ago

    Here’s why Amazon won’t go into pharma: hedge fund billionaire

    Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.